Jaffetilchin Investment Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.1M | Sell |
17,545
-1,130
| -6% | -$1.15M | 0.96% | 24 |
|
|
2025
Q4 | $20.1M | Sell |
18,675
-313
| -2% | -$299K | 1.17% | 23 |
|
|
2025
Q3 | $14.5M | Buy |
18,988
+1,653
| +10% | +$1.23M | 0.87% | 27 |
|
|
2025
Q2 | $13.5M | Buy |
17,335
+2,348
| +16% | +$1.82M | 0.88% | 27 |
|
|
2025
Q1 | $12.4M | Buy |
14,987
+102
| +0.7% | +$84.9K | 0.9% | 25 |
|
|
2024
Q4 | $11.5M | Buy |
14,885
+268
| +2% | +$222K | 0.83% | 26 |
|
|
2024
Q3 | $12.9M | Buy |
14,617
+693
| +5% | +$623K | 0.98% | 24 |
|
|
2024
Q2 | $12.6M | Buy |
13,924
+173
| +1% | +$138K | 1.08% | 24 |
|
|
2024
Q1 | $10.7M | Buy |
13,751
+379
| +3% | +$270K | 0.96% | 25 |
|
|
2023
Q4 | $7.79M | Sell |
13,372
-499
| -4% | -$291K | 0.76% | 30 |
|
|
2023
Q3 | $7.45M | Buy |
13,871
+210
| +2% | +$108K | 0.82% | 33 |
|
|
2023
Q2 | $6.41M | Sell |
13,661
-684
| -5% | -$287K | 0.68% | 35 |
|
|
2023
Q1 | $4.93M | Buy |
14,345
+1,138
| +9% | +$384K | 0.56% | 43 |
|
|
2022
Q4 | $4.83M | Sell |
13,207
-218
| -2% | -$77.3K | 0.59% | 41 |
|
|
2022
Q3 | $4.34M | Buy |
13,425
+498
| +4% | +$158K | 0.56% | 36 |
|
|
2022
Q2 | $4.19M | Buy |
12,927
+540
| +4% | +$162K | 0.5% | 41 |
|
|
2022
Q1 | $3.61M | Buy |
12,387
+1,868
| +18% | +$481K | 0.43% | 44 |
|
|
2021
Q4 | $2.9M | Sell |
10,519
-778
| -7% | -$197K | 0.27% | 65 |
|
|
2021
Q3 | $2.61M | Sell |
11,297
-6,911
| -38% | -$1.71M | 0.28% | 65 |
|
|
2021
Q2 | $3.75M | Buy |
18,208
+9,206
| +102% | +$1.85M | 0.26% | 72 |
|
|
2021
Q1 | $1.68M | Buy |
9,002
+1,890
| +27% | +$370K | 0.2% | 93 |
|
|
2020
Q4 | $1.2M | Buy |
7,112
+3,075
| +76% | +$459K | 0.17% | 93 |
|
|
2020
Q3 | $598K | Buy |
4,037
+1,856
| +85% | +$287K | 0.11% | 109 |
|
|
2020
Q2 | $358K | Sell |
2,181
-366
| -14% | -$56.2K | 0.08% | 157 |
|
|
2020
Q1 | $353K | Buy |
2,547
+607
| +31% | +$83.4K | 0.12% | 107 |
|
|
2019
Q4 | $255K | Sell |
1,940
-64
| -3% | -$7.42K | 0.06% | 184 |
|
|
2019
Q3 | $224K | Sell |
2,004
-161
| -7% | -$17.9K | 0.05% | 201 |
|
|
2019
Q2 | $240K | Sell |
2,165
-996
| -32% | -$117K | 0.06% | 220 |
|
|
2019
Q1 | $410K | Sell |
3,161
-993
| -24% | -$121K | 0.09% | 178 |
|
|
2018
Q4 | $481K | Buy |
4,154
+1,679
| +68% | +$188K | 0.12% | 131 |
|
|
2018
Q3 | $266K | Buy |
+2,475
| New | +$247K | 0.06% | 246 |
|
|
2017
Q4 | – | Sell |
-10,628
| Closed | -$909K | – | 269 |
|
|
2017
Q3 | $909K | Buy |
10,628
+5,789
| +120% | +$475K | 0.21% | 80 |
|
|
2017
Q2 | $398K | Sell |
4,839
-3,086
| -39% | -$252K | 0.13% | 133 |
|
|
2017
Q1 | $667K | Buy |
+7,925
| New | +$635K | 0.17% | 99 |
|
Other funds holding LLY
VCM
VPM
Jaffetilchin Investment Partners's LLY Position: Q1 2026 in Review
Jaffetilchin Investment Partners reduced its Eli Lilly (LLY) stake by 6.1% in Q1 2026, selling an estimated $1.15M and leaving 17,545 shares worth $16.1M. The position accounts for 0.96% of the portfolio, ranked #24.
Jaffetilchin Investment Partners first reported a position in LLY in Q1 2017 and has held it in 34 quarters since. The position peaked at $20.1M in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Jaffetilchin Investment Partners held 17,545 shares of Eli Lilly worth $16.1M as of Q1 2026.
- Jaffetilchin Investment Partners sold 1,130 Eli Lilly shares in Q1 2026, an estimated $1.15M.
- Eli Lilly made up 0.96% of Jaffetilchin Investment Partners's portfolio in Q1 2026, its #24 holding.
- Jaffetilchin Investment Partners first reported a position in Eli Lilly in Q1 2017 and has held it in 34 quarters since.
- Jaffetilchin Investment Partners's Eli Lilly position peaked at $20.1M in Q4 2025.
- 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Jaffetilchin Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.